US-based company licenses innovative depression treatment from CAMH

Collaboration agreementToronto, ON – The Centre for Addiction and Mental Health (CAMH) and U.S.-based Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.

Please Login to view this Content. (Not a member? Join Today!)
Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.